




RealRate

PHARMACEUTICAL 2020

Amneal Pharmaceuticals Inc.
Rank 103 of 362



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai



RealRate

PHARMACEUTICAL 2020

Amneal Pharmaceuticals Inc.
Rank 103 of 362



The relative strengths and weaknesses of Amneal Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Amneal Pharmaceuticals Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 203% points. The greatest weakness of Amneal Pharmaceuticals Inc. is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 114% points.

The company's Economic Capital Ratio, given in the ranking table, is -45%, being 258% points above the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	1,210,210
Cost of Goods Sold	1,147,214
Intangible Assets	1,802,257
Liabilities, Current	550,406
Liabilities, Non-Current	2,768,696
Other Assets	175,426
Other Compr. Net Income	250,151
Other Expenses	621,083
Other Liabilities	0
Other Net Income	15,998
Property and Equipment	477,997
Research and Development	188,049
Revenues	1,626,373
Selling, General and Administrative Expense	289,598

Output Variable	Value in 1000 USD
Assets	3,665,890
Liabilities	3,319,102
Expenses	2,245,944
Stockholders Equity	346,788
Net Income	-603,573
Comprehensive Net Income	-478,498
Economic Capital Ratio	-45%



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai